Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2000003127

Enrollment

Unknown

Registered

2020-03-15

Start date

2020-02-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

experimental group:Oral Chinese medicine "qingfei detoxification soup" + intravenous injection of ulinastatin 200000 U Bid.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The confirmed patients with common type of new coronavirus pneumonia were selected, and the diagnostic criteria were shown in [diagnosis and treatment scheme 5.0 for pneumonia caused by new coronavirus infection].

Exclusion criteria

Exclusion criteria: 1. Aged > 75 years old and < 18 years old; 2. Patients who are contraindicated or allergic to this study drug (lung-clearing and detoxification decoction and ulinastatin for injection); 3. Patients with previous tumor, severe liver disease, pulmonary fibrosis, tuberculosis, autoimmune diseases, and treatment with glucocorticoids and immunosuppressive agents; 4. The diagnostic criteria for severe patients with novel coronavirus pneumonia were [novel coronavirus infection pneumonia treatment scheme 5.0].

Design outcomes

Primary

Measure	Time frame
blood clotting function;ABG;liver and kidney function;blood RT;	—

Countries

China

Contacts

Public ContactJIAN PENG

Wuhan third hospital

137585260@qq.com+86 13907105212

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026